Vive Diagnostics, an IVD company based in Singapore and Shanghai, China, that focuses on chronic diseases, cancer, and infectious disease, has raised $100M in Series A funding.
Sequoia China and Morningside Ventures led the round with participation by ORIZA Holdings and Lilly Asia Ventures and PerkinElmer Ventures.
The company plans to use the funds for IVD products in selected emerging markets.
Johnson Zhang is the CEO of Virtue Diagnostics, a platform-based IVD (In Vitro Diagnostics) company that focuses on affordable clinical solutions for all stages of disease, including early screening, initial diagnosis and treatment monitoring.
Virtue Diagnostics Corporate headquarters and R&D headquarters can be found in Singapore. Manufacturing is located in Suzhou, China, and CRO/Clinical Lab in Beijing.